List of interesting CML Publications
Please click here to find a selection of other recent clinical and scientific CML publications from peer-reviewed journals.
CML Publications 2016 |
|
Clinical Publications | Scientific Publications |
March 2016 | |
Splenic irradication before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study |
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance (Patkar N et al. Leuk Lymphoma, March 2016) (epub ahead of print) |
Rotation of nilotinib and imatinib for first-line treatment of chronic myeloid leukemia (Gugliotta G. Am J Hematol, March 2016) (epub ahead of print) |
Micro RNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia (Chakraborty C. et al. Oncotarget, March 2016) (epub ahead of print) |
Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States |
Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3 (Wang H et al. Oncotarget, March 2016) (epub ahead of print) |
New methodologies in the molecular monitoring of CML |
NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells |
Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and/or renal dysfunction (Sasaki K et al. Clin Lymphoma Myeloma Leuk, March 2016) |
c-MYB is a transcriptional regulator of ESPL1/separase in BCR-ABL-positive chronic myeloid leukemia (Prinzhorn W et al. Biomark Res, March 2016) (epub ahead of print) |
Present and future of molecular monitoring in chronic myloid leukaemia (Soverini S et al. Br J Haematol, March 2016) (epub ahead of print) |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients (Alikian M et al. J Mol Diagn, March 2016) |
Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era? (Bansal A et al. Curr Opin Hematol, March 2016) (epub ahead of print) |
|
February 2016 | |
Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study (Cortes JE et al. Clin Lymphoma Myeloma Leuk, February 2016) (epub ahead of print) |
High CIP2A levels correlates with an antiapoptoic phenotype that can be overcome by targeting BCL-XL in chronic meyloid leukemia (Lucas CM et al. Leukemia, February 2016) (epub ahead of print) |
Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia (Caldemeyer L et al. Curr Hematol Malig Rep, February 2016) (epub ahead of print) |
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib resistance preventing rpS6 phosphorylation in chronic meyloid leukaemia cells: new combined therapeutic strategies |
Hematologic malignancies in pregnancy: Management guidelines from an international consensus (Lishner M et al. J Clin Oncol, February 2016) |
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukemia (Latham S et al. J Clin Pathol, February 2016) (epub ahead of print) |
Quality of life and long-term therapy in patients with chronic myeloid leukemia |
Hsp90 inhibitor, BIIBo21, induces apoptosis and authopagy by regulating mTOR-UIIK1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemic cells (He W et al. Int J Oncol, February 2016) |
Omacetaxine Mepesuccinate for chronic myeloid leukemia |
Normal ABL1 is a tumour suppressor and therapeutic target in human and mouse leukemias expressing oncogeneic ABL1 kinase (Dasgupta Y et al. Blood, February 2016) |
Analysis of 2013 European LeukemiaNET (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcome (Jain P et al. Br. J Hematol, February 2016) |
Heterogeneity of leukemia-initiating capacity of chronic meylogenous leukemic stem cells (Zhang B et al. J Clin Invest, February 2016) (epub ahead of print) |
Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring (Jabbour E et al. Am J Hematol, February 2016) |
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients (Deiniger MW et al. Blood, February 2015) |
Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response and overall survival: A systemic review and meta-analysis (Douxfils J et al. JAMA Oncol, February 2016) (epub ahead of print) |
The role of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review (Di Stefano C et al. Oncol Rep, February 2016) |
The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients (Kurtovic-Kozaric A et al. Br J Haematol, February 2016) (epub ahead of print) |
|
Allogeneic transplantation for CML in the TKI era: striking the right balance (Innes AJ et al. Nat Rev Clin Oncol, February 2016) |
|
January 2016 | |
Conditional survival with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2016) |
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib (Parker WT et al. Blood, January 2016) (epub ahead of print) |
Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France intergroup des leucémies myéloides chroniques (Rea D et al. Bull Cancer, January 2016) |
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia (Tanrikulu Simsek E et al. J Clin Pathol, January 2016) |
Dasatinib first-line: Multicentric Italian experience outside clinical trials (Breccia M et al. Leuk Res, January 2016) |
Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (epub ahead of print) |
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (Pfirrmann M et al. Leukemia, January 2016) |
Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis |
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase myeloid leukaemia resistant or intolerant to imatinib (Brümmendorf TH et al. Br J Haematol, January 2016) (epub ahead of print) |
In silico identifcation of inhibitors against mutated BCR-ABL protein screening and molecular dynamics simultation study (Kumar H et al. J Biomol Struct Dyn, January 2016) (epub ahead of print) |
Conditioned survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2015) |
|
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase (Akard LP et al. Leuk Lymphoma, January 2016) (epub ahead of print) |
CML Publications 2014/2015
Access 2015 CML publications here
Access 2014 CML publications here
Search for more publications on CML at PubMed.gov